SMS PHARMACEUTICALS
|
SMS PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 |
| CEPS(Rs) | 11.48 | 9.54 | 4.25 | 11.82 | 9.83 |
| DPS(Rs) | 0.40 | 0.40 | 0.30 | 0.30 | 0.30 |
| Book NAV/Share(Rs) | 70.36 | 59.98 | 54.40 | 55.56 | 48.50 |
| Tax Rate(%) | 27.01 | 25.57 | 27.39 | 0.90 | 33.09 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.42 | 15.27 | 9.87 | 20.69 | 19.94 |
| EBIT Margin(%) | 13.10 | 11.73 | 4.94 | 15.83 | 16.84 |
| Pre Tax Margin(%) | 10.91 | 8.64 | 0.97 | 12.37 | 15.00 |
| PAT Margin (%) | 7.96 | 6.43 | 0.70 | 12.25 | 10.04 |
| Cash Profit Margin (%) | 12.02 | 10.55 | 6.52 | 18.06 | 13.70 |
| Performance Ratios | |||||
| ROA(%) | 6.07 | 5.10 | 0.44 | 7.97 | 8.44 |
| ROE(%) | 11.91 | 10.16 | 0.83 | 15.41 | 16.07 |
| ROCE(%) | 12.55 | 11.73 | 3.79 | 12.60 | 17.62 |
| Asset Turnover(x) | 0.76 | 0.79 | 0.63 | 0.65 | 0.84 |
| Sales/Fixed Asset(x) | 1.22 | 1.27 | 0.97 | 0.98 | 1.32 |
| Working Capital/Sales(x) | 3.68 | 3.78 | 3.55 | 3.07 | 5.33 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.82 | 0.79 | 1.04 | 1.02 | 0.76 |
| Receivable days | 94.73 | 91.77 | 65.01 | 50.80 | 46.40 |
| Inventory Days | 111.76 | 109.10 | 156.71 | 128.12 | 80.21 |
| Payable days | 110.75 | 111.30 | 97.98 | 91.63 | 59.01 |
| Valuation Parameters | |||||
| PER(x) | 27.27 | 30.25 | - | 12.76 | 16.84 |
| PCE(x) | 18.53 | 18.67 | 13.59 | 7.94 | 12.65 |
| Price/Book(x) | 3.02 | 2.97 | 1.06 | 1.69 | 2.57 |
| Yield(%) | 0.19 | 0.22 | 0.52 | 0.32 | 0.24 |
| EV/Net Sales(x) | 2.75 | 2.47 | 1.41 | 1.94 | 2.24 |
| EV/Core EBITDA(x) | 14.84 | 14.45 | 12.35 | 8.41 | 10.14 |
| EV/EBIT(x) | 19.43 | 19.52 | 26.88 | 11.49 | 12.35 |
| EV/CE(x) | 2.27 | 2.14 | 1.03 | 1.15 | 1.53 |
| M Cap / Sales | 2.41 | 2.13 | 0.94 | 1.53 | 1.87 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.36 | 35.86 | 0.42 | -7.69 | 36.71 |
| Core EBITDA Growth(%) | 19.80 | 103.90 | -50.38 | -3.83 | 46.34 |
| EBIT Growth(%) | 23.61 | 228.30 | -68.83 | -14.31 | 62.21 |
| PAT Growth(%) | 36.99 | 1,166.70 | -94.28 | 11.34 | 86.50 |
| EPS Growth(%) | 32.49 | 805.84 | -111.35 | -0.49 | 98.04 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.50 | 0.55 | 0.55 | 0.55 | 0.61 |
| Current Ratio(x) | 1.67 | 1.58 | 1.61 | 1.85 | 1.54 |
| Quick Ratio(x) | 0.84 | 0.91 | 0.73 | 0.67 | 0.89 |
| Interest Cover(x) | 5.98 | 3.80 | 1.24 | 4.57 | 9.14 |
| Total Debt/Mcap(x) | 0.16 | 0.19 | 0.52 | 0.33 | 0.24 |
Compare Financial Ratios of peers of SMS PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SMS PHARMACEUTICALS | ₹3,652.0 Cr | 4.5% | 26% | 87.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹428,185.0 Cr | 3.5% | 12.3% | 5.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,766.0 Cr | 2.8% | 7.2% | 7.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹148,923.0 Cr | 3.8% | 12.1% | 42.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,081.0 Cr | 3% | 9.1% | 11.6% | Stock Analytics | |
| CIPLA | ₹109,680.0 Cr | 1.2% | 2.8% | -9.1% | Stock Analytics | |
SMS PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SMS PHARMACEUTICALS | 4.5% |
26% |
87.4% |
| SENSEX | -0.3% |
-0.1% |
8.3% |
You may also like the below Video Courses
